Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Status:
Completed
Trial end date:
2017-04-07
Target enrollment:
Participant gender:
Summary
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on
diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood
pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood
pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral
regimen of 4 doses of ACT-132577.